Free Trial Information
BioCentury | Nov 10, 2014
Clinical News

NKTT120 regulatory update

...for the indication, for which the product also has Orphan Drug designation in the U.S. NKT Therapeutics Inc....
Read More
BioCentury | Jan 13, 2014
Clinical News

NKTT120: Interim Phase I data

...II trials with NKTT120 are planned after the optimal dose of the compound is determined. NKT Therapeutics Inc....
Read More
BioCentury | Oct 11, 2010
Company News

NKT Therapeutics management update

NKT Therapeutics Inc. , Waltham, Mass. Business: Inflammation, Cancer, Autoimmune Hired: Barbara Finck as CMO, formerly SVP of R&D and CMO at Osprey Pharmaceuticals U.S.A. Inc. WIR Staff...
Read More
BioCentury | Jun 10, 2010
Distillery Techniques

Technology: Drug platforms

...steps include identifying other serum proteins with NK cell-stimulating activity. Wittycell S.A.S., Cytheris S.A. and NKT Therapeutics Inc....
Read More
BioCentury | Jan 25, 2010
Finance

SVLS closes V fund

...technology company Juvaris BioTherapeutics Inc. , respiratory company Mpex Pharmaceuticals Inc. , immune modulator company NKT Therapeutics Inc....
Read More
BioCentury | Oct 26, 2009
Company News

NKT Therapeutics, Kyowa Hakko Kirin deal

...upfront payment and is eligible for development milestones and royalties. Further terms were not disclosed. NKT Therapeutics Inc....
Read More
BioCentury | Apr 6, 2009
Company News

NKT Therapeutics board of directors update

NKT Therapeutics Inc. , Newton, Mass. Business: Inflammation, Cancer, Autoimmune Appointed: Michael Ross, managing partner at SV Life Sciences; and Joseph Amprey, senior managing director of MedImmune Ventures WIR Staff...
Read More
Items per page:
1 - 7 of 7
BioCentury | Nov 10, 2014
Clinical News

NKTT120 regulatory update

...for the indication, for which the product also has Orphan Drug designation in the U.S. NKT Therapeutics Inc....
Read More
BioCentury | Jan 13, 2014
Clinical News

NKTT120: Interim Phase I data

...II trials with NKTT120 are planned after the optimal dose of the compound is determined. NKT Therapeutics Inc....
Read More
BioCentury | Oct 11, 2010
Company News

NKT Therapeutics management update

NKT Therapeutics Inc. , Waltham, Mass. Business: Inflammation, Cancer, Autoimmune Hired: Barbara Finck as CMO, formerly SVP of R&D and CMO at Osprey Pharmaceuticals U.S.A. Inc. WIR Staff...
Read More
BioCentury | Jun 10, 2010
Distillery Techniques

Technology: Drug platforms

...steps include identifying other serum proteins with NK cell-stimulating activity. Wittycell S.A.S., Cytheris S.A. and NKT Therapeutics Inc....
Read More
BioCentury | Jan 25, 2010
Finance

SVLS closes V fund

...technology company Juvaris BioTherapeutics Inc. , respiratory company Mpex Pharmaceuticals Inc. , immune modulator company NKT Therapeutics Inc....
Read More
BioCentury | Oct 26, 2009
Company News

NKT Therapeutics, Kyowa Hakko Kirin deal

...upfront payment and is eligible for development milestones and royalties. Further terms were not disclosed. NKT Therapeutics Inc....
Read More
BioCentury | Apr 6, 2009
Company News

NKT Therapeutics board of directors update

NKT Therapeutics Inc. , Newton, Mass. Business: Inflammation, Cancer, Autoimmune Appointed: Michael Ross, managing partner at SV Life Sciences; and Joseph Amprey, senior managing director of MedImmune Ventures WIR Staff...
Read More
Items per page:
1 - 7 of 7